We have evaluated the production of PRL by human peripheral mononuclear cells (PBMNC) from normal subjects and patients with systemic lupus erythematosus (SLE). Conditioned medium prepared from basal and Con-A-stimulated PBMNC was assessed for the presence of PRL-like by its ability to stimulate growth of PRL-responsive Nb2 rat lymphoma cells. In the presence or absence of Con-A, SLE PBMNC secrete significantly higher (P Ͻ 0.001) amounts of bioactive PRL-like species than normal cells. Growth of Nb2 cells by conditioned medium was inhibited with specific antiserum to human PRL.
T HE PARTICIPATION of PRL in immunity has been derived from studies demonstrating the importance of exogenous PRL in restoring immune competence in hypophysectomized animals (1, 2) . Thereafter, studies on the induction of immunosuppression by bromocriptine, a potent inhibitor of endogenous PRL (3) (4) (5) (6) (7) , together with the antagonistic actions of this pituitary hormone on the immunosuppressive effects of glucocorticoids and cyclosporine (8) have established the immunomodulatory role of PRL.
The immune-stimulating properties of PRL have been clearly demonstrated in both central and peripheral lymphoid organs (9) , especially in the rat Nb2 T lymphoma cell line, which requires PRL for T cell proliferation (10, 11) . In animal studies, PRL seems to be involved in maintaining the competence of B and T lymphocytes (2, 3) as well as enhancing macrophage cytotoxicity (4) . In addition, PRL might affect thymic embryonic differentiation (12) and thereby influence neonatal T cell development (13) . These observations have been further supported by the identification in a number of mammalian species, including man, of high affinity binding sites and the expression of PRL receptor genes in hematopoietic cells (14 -18) . This receptor has been shown to be a member of the superfamily of cytokine receptors involved in the growth and differentiation of lymphohematopoietic lineages (19) .
A consistent finding in a number of studies has been the ability of PRL antisera to block the in vitro mitogen-stimulated murine, marmoset, and human lymphocyte proliferation (20) . This effect was not seen with antibodies to GH or other trophic hormones (20) . These observations suggest the presence of a locally produced PRL-like molecule that, acting in an autocrine or paracrine manner with PRL receptors in lymphocytes, could stimulate cell proliferation. In this regard, direct evidence of PRL-like message and secretion of structural and bioactive PRL-like molecules by murine (21) and human lymphocytes has been conclusively provided (17) .
It is now becoming clear that conditions such as hyperprolactinemia are accompanied by immune T cell alterations (22, 23) and reduced natural killer cell number (24) and function (5, 6, 22) . These PRL-mediated abnormalities appear to predispose the susceptible host for antibody-and cellmediated autoimmune disease. In both humans (25, 26) and the naturally occurring lupus B/W mouse model (27) , sys-temic lupus erythematosus (SLE) is aggravated by altering normal serum PRL levels. In the present study, we have determined whether mitogen-stimulated mononuclear cells in patients with SLE differ from those in normal subjects in terms of the synthesis and secretion of PRL in vitro as an strategy to study the association of PRL with this particular autoimmune disorder.
Materials and Methods
The study protocol was approved by the human ethical committee of the institute, and informed written consent was obtained from all subjects who volunteered to participate in this study.
Patients and controls
Eight female patients with diagnosis of SLE and with no evidence of endocrine disease were studied. Their ages ranged from 17-36 yr (mean, 26 yr). All patients fulfilled at least four of the American Rheumatism Association revised criteria (28) . None of the patients were receiving corticosteroids or immunosuppressive or nonsteroidal antiinflammatory drugs at the time of the study. Clinical disease activity was scored on a 0 -32 point scale according to the MEX-SLEDAI index (29) . Patients with a MEX-SLEDAI score greater than or equal to 2 points were considered active. Six patients were active according to the above criteria. Eleven healthy ovulatory women (aged 21-50 yr) were studied as controls. None of the SLE or control subjects were receiving drugs known to be associated with increased PRL secretion.
Cell preparation and cultures
Human peripheral blood mononuclear cells (PBMNC) were obtained by Ficoll-Hypaque separation (30) of heparinized venous blood obtained from normal and SLE subjects. PBMNC were recovered from the interface and cultured at a concentration of 2 ϫ 10 5 cells/0.15 mL in serumfree culture medium (AIM-V Medium, Life Technologies, Grand Island, NY) in the presence of various concentrations of Con-A. The viability of cells, as determined by trypan blue exclusion, was always above 95%. Cells were incubated for 72 h at 37 C in a humidified 95% air-5% CO 2 atmosphere. Culture medium was kept at Ϫ20 C until analyzed for PRL bioactivity. DNA synthesis was evaluated by the addition of 1.0 Ci 
PRL-dependent Nb2 lymphoma cells
The Nb2 cell line was originally obtained from Dr. P. W. Gout (Vancouver, Canada). PRL bioactivity was measured using the Nb2 lymphoma cell assay as described by Tanaka et al. (11) with minor modifications. Briefly, cells were kept at 37 C in Fisher's medium containing 10% FBS as a source of lactogen, 10% horse serum, 10 Ϫ4 mol/L 2-mercaptoethanol, 50 IU/mL penicillin, and 50 g/mL streptomycin. The cells were arrested in the early G 1 phase of the cell cycle by preincubation (18 -24 h) in lactogen-free medium. At this time, resumption of the cell cycle was stimulated by the addition of increasing concentrations of highly purified human pituitary PRL (NIDDK hPRL RP-2). PRL-like bioactivity was assayed in aliquots of culture medium from PBMNC at different dilutions to ascertain parallelism with the standard curve. Cultures per duplicate were further maintained in an atmosphere of 95% air-5% CO 2 at 37 C for 72 h. The effects of hPRL or culture medium on cell proliferation were analyzed by the incorporation of [
3 H]thymidine (1.0 Ci) into Nb2 cells. The sensitivity of this assay for PRL was 1.0 pg/mL.
Complementary DNA (cDNA) synthesis and PCR amplifications
Total ribonucleic acid (RNA) was isolated from cultured PBMNC as described by Chomzynski and Sacchi (31) . One microgram of total RNA was used as a template for cDNA synthesis, using cloned Moloney murine leukemia virus reverse transcriptase (RT; Perkin-Elmer, Norwalk, CT). The following are the sequences used for the sense and antisense primers for PCR amplification of hPRL cDNA (complementary to exons 2 and 5, respectively): PRL 1 , 5Ј-TGTCAAACCTGCTCCTGT-GCCAGA-3Ј; and PRL 2 , 5Ј-GTTGTTGTTGTGGATGATTCGGCA-3Ј. To monitor efficiency for the RT reaction, we used as a control the amplification of the ubiquitous protein cyclophilin (CF) with the following sense and antisense primers, respectively: CF 1 , 5Ј-CCGCGTCTCCTTT-GAGCTGTTT-3Ј; and CF 2 , 5Ј-ACCCAAAGGGAACTGTGCAGC-GAGAGC-3Ј. These primers generate a single 633-and 569-bp PRL and CF RT-PCR product, respectively. All oligonucleotides were synthesized in a DNA synthesizer model 391 (Applied Biosystems, Perkin-Elmer/ Cetus Co., Norwalk, CT). PCR was carried out with the use of 20 L of each of the RT reaction products containing a final concentration of 0.5 mol/L of each primer, 2.5 U Taq polymerase, and 0.2 mmol/L deoxy (d)-NTPs in a final incubation volume of 0.1 mL. Amplification was performed on a Perkin-Elmer/Cetus 9600 PCR instrument beginning with a denaturation step at 95 C for 105 s, followed by 35 cycles at 95 C for 15 s and 55 C for 30 s, with a final 7-min extension at 72 C. Aliquots (10 L) of each PCR were analyzed on 5% polyacrylamide gels (Bio-Rad, Hercules, CA) to monitor the specificity and the amount of product as described previously (32) . Double distilled water or incubations in the absence of RT were used as controls for RT-PCR reactions. A band of the predicted size (633 bp) was confirmed as hPRL by Southern blot analysis of previously separated DNA on 5% polyacrylamide gels with a hPRL cDNA probe radiolabeled with [ 32 P]dCTP. A plasmid containing the 914-bp hPRL cDNA, originally obtained from Dr. Nancy Cooke, University of Pennsylvania (Philadelphia, PA), was grown in DH5␣ Escherichia coli, excised and purified as previously reported (33), and radiolabeled with [ 32 P]dCTP with the use of a random primer kit (Life Technologies, Gaithersburg, MD).
Western blotting and immunostaining
PBMNC extracts were homogenized in 50 mmol/L Tris (pH 8.0), 150 mmol/L NaCl, and 1% (vol/vol) Triton X-100 containing phenylmethylsulfonylfluoride (100 g/mL) and aprotinin (1 g/mL) and centrifuged at 8000 ϫ g for 10 min, and supernatants were saved at Ϫ20 C until assayed. Culture media from PBMNC were immunoprecipitated using the VLS-2 anti-hPRL antiserum (Dr. Y. N. Sinha, Whittier Institute for Diabetes and Endocrinology, La Jolla, CA) for 72 h at 4 C. The precipitates were obtained after the addition of goat antirabbit ␥-globulin as previously described (34) , and cell extracts were resuspended and dissolved in Laemmli's sample buffer and heated at 95 C for 5 min. Samples were electrophoresed on 12% polyacrylamide slab gels in the presence of SDS (SDS-PAGE) under reducing conditions (35) . After electrophoresis, proteins were electroblotted onto nitrocellulose membranes in PAGE buffer containing 20% methanol without SDS (36) . Membranes were fixed, blocked, and incubated overnight at room temperature in a 1:1000 final dilution of anti-hPRL serum VLS-2 in 0.01 mol/L Tris-buffered saline, pH 7.4, containing 0.1% Tween-20 and 3% Carnation powered non-fat dry milk (Carnation, Los Angeles, CA). Immunocomplexes were visualized by autoradiography after incubation in 125 I-labeled protein A (200,000 cpm/mL). After several washes in Tris-buffered saline, the paper was dried and autoradiographed.
Hormonal assays
Blood samples were allowed to clot at room temperature, then were centrifuged at 1000 ϫ g, and supernatants were stored at Ϫ20 C until assayed. PRL was measured in duplicate by specific RIA, using reagents and protocols provided by the National Hormone Pituitary Program (Rockville, MD) as previously described (37) . The within-assay coefficient of variation for PRL was 7.0 Ϯ 0.5%, with a sensitivity of 1.5 g/L.
Statistical analysis
Differences between groups were assessed by using the Mann-Whitney U test. P Ͻ 0.05 was considered significantly different.
Results

Baseline levels of serum PRL
Mean radioimmunoassayable PRL concentrations in serum from SLE and control subjects were within the normal values established in our laboratory (3-19 g/L). However, serum PRL levels in SLE individuals (19.0 Ϯ 5.3 g/L) were significantly higher than those in the normal group (12.7 Ϯ 4.9 g/L; P Ͻ 0.01). Two SLE subjects had circulating PRL concentrations slightly above normal values (27 and 25 g/L, respectively) without clinical manifestations of hyperprolactinemia.
Nb2 cell bioassay, parallelism and responsiveness to Con-A
As shown in Fig. 1 , Nb2 when exposed to hPRL incorporated [ 3 H]thymidine in a dose-response manner (solid line). A parallel dose-response curve was obtained when different aliquots of the supernatant from a lupic PBMNC culture were added (dotted line). Nb2 cells were also exposed to various concentrations of Con-A, a well known stimulator of human lymphocytes. Over the concentration ranges tested, mitogenic indexes were not significantly different from those obtained without mitogen (Fig. 2) . Thus, these data indicate that Con-A at concentrations that normally stimulate human lymphocytes had no mitogenic effects on the Nb2 cells.
Production of bioactive PRL-like by cultured PBMNC
At a concentration of 2 ϫ 10 5 cells in the presence of 1.5 g/mL of Con-A, PBMNC from normal and SLE subjects produced the highest PRL-like bioactivity in the Nb2 mitogenic assay. In all cases, basal PRL-like bioactivity increased significantly in PBMNC cultured in the presence of the mitogen; however, the major increments in response to Con-A were always observed in control cells.
The production of bioactive PRL-like by PBMNC cultured in serum-free media from SLE and normal subjects is shown in Fig. 3 . As can be seen, non-Con-A-stimulated (B) PBMNC from SLE subjects produced significantly higher (P Ͻ 0.001) amounts of bioactive PRL-like (195 Ϯ 47 pg/mL) than nonstimulated PBMNC from normal individuals (27 Ϯ 4 pg/ mL). Stimulation with Con-A (S) increased PRL-like bioactivity in both normal (148 Ϯ 19 pg/mL) and SLE-PBMNC (280 Ϯ 46 pg/mL). Although, normal cells responded better to the mitogen, stimulated SLE cells produced significantly higher amounts of bioactive PRL (P Ͻ 0.05 vs. normal).
To evaluate the PRL-like specificity of the mitogenic activity found in PBMNC from normal and SLE subjects, a specific antiserum to hPRL (VLS-2 hPRL antiserum) was added together with the samples to the Nb2 cell bioassay. As depicted in Fig. 3 , hPRL antiserum blocked the proliferative activity of medium from Con-A-stimulated normal and SLE PBMNC cultures. Although, the mitogenic activity in SLE remained higher than that in control subjects (P Ͻ 0.05), the inhibitory effect of PRL antiserum was statistically significant in both cases (P Ͻ 0.01; Con-A-stimulated vs. antibody).
Western blot analysis of bioactive PRL-like molecules
To further evaluate the nature of bioactive PRL-like molecules secreted by PBMNC from normal and SLE subjects, cell extracts were prepared and subjected to SDS-PAGE. A single 60-kDa immunoreactive PRL product was found in Western blots from both SLE (Fig. 4, lanes 3 and 4) and control (Fig. 4 , lanes 5 and 6) Con-A stimulated PBMNC. As shown, SLE lymphoid cells contained more 60-kDa PRL than normal cells. There was no evidence for the existence of 23-kDa PRL like that found in circulation of a patient with Fig. 4, lane 2) or of any other PRL-like variants previously described. A highly purified PRL preparation from human pituitaries (NIDDK hPRL RP-2) was used as the standard for electrophoretical mobility (Fig. 4, lane 1) . Control incubations with normal rabbit serum instead of PRL antiserum gave negative results.
SLE (
PRL messenger RNA (mRNA) in normal and SLE PBMNC
To determine whether the PRL gene is expressed in normal and SLE PBMNC, PRL gene sequences were amplified by reverse transcription followed by PCR. A 914-bp hPRL cDNA probe was used as a control for PCR product size determination. Figure 5 shows a representative Southern blot analysis of RT-PCR products obtained from Con-A-stimulated normal and SLE PBMNC. As depicted, a major fragment of 633 bp was generated in both SLE and normal PBMNC cDNAs (upper panel, lanes 2 and 3, respectively) with an identical size as that obtained with the hPRL cDNA probe used as a positive control (upper panel, lane 1). Control amplifications using CF are shown in the bottom panel. In the absence of RT, none of the mRNA samples from SLE and normal PBMNC cDNAs for PRL and CF, respectively, gave positive results. Similar negative results were obtained when double distilled water was used instead of mRNA (data not shown).
Discussion
The association between the neuroendocrine and the immune systems has been strengthened and considered increasingly important since the demonstration of PRL-like molecules and PRL-binding sites in human PBMNC (14 -17) . There is now evidence suggesting that PRL may have a role in the pathogenesis of a number of autoimmune processes (38) . It has been demonstrated that PRL is comitogenic on murine and human lymphocytes, induces IL-2 receptor expression (39, 40) , and stimulates antibody production (41) . These data together with the observation that human PBMNC actively synthesize PRL suggest that this protein acts as an autocrine growth factor for lymphoproliferation (42) . In the case of SLE, its predilection for women of reproductive age and pregnancy are indicators that reproductive hormones influence lupus. Studies by Jara et al. (43) showing elevated serum PRL levels in a subset of subjects affected with active SLE together with data from the autoimmune female New Zealand Black/New Zealand White F1 (B/W) mouse model (27) strongly suggest that PRL may be associated with disease activity in SLE.
In this study, we have shown the presence of a PRL mRNA transcript in Con-A-stimulated PBMNC from subjects with SLE. In addition, conditioned medium from Con-A-stimulated PBMNC from SLE subjects showed a higher biological activity in the Nb2 cell bioassay than that from normal subjects. It was not possible to determine the mechanisms influencing the rate of PRL gene expression in SLE or whether it depends on clinical disease activity. Recently, Gutiérrez et al. (44) showed that both nonstimulated and stimulated PBMNC from patients with SLE have an increased production of PRL-like immunoreactive material. The immunoreactive PRL concentration in the culture medium found by these authors was nearly 3 times higher than the amount detected with the bioassay used in this study. Nothing is known concerning the immuno/bioactivity ratios of lymphocyte-derived PRL, especially under pathological conditions such as SLE. In this regard, several PRL variants with different bioactivities have been described and formed by transcriptional or translational mechanisms (45) . In contrast to the 11-kDa PRL-like species reported by Gutierrez et al. (44) in peripheral lymphocytes from SLE, our results revealed the presence of a 60-kDa PRL-like variant as the major immunoreactive lymphocyte-derived PRL form. This species did express PRL-like bioactivity in the Nb2 node lymphoma bioassay, and its proliferative actions on these cells were suppressed when polyclonal anti-hPRL was added to the cultures. These data are consistent with studies that demonstrated the presence of PRL-like variants with molecular sizes ranging from 11-60 kDa in human lymphocytes (42) and may also explain in part the apparent discrepancy with our results in terms of PRL immunoreactivity and bioactivity in lymphocytes from SLE individuals. Inasmuch as the RT-PCR reaction produced a single expected 633-bp band that was further confirmed by Southern analysis with the use of hPRL cDNA as the probe, it is suggested that the size variation observed in lymphocyte-derived PRL is probably due to posttranslational modifications of a common precursor. Additional experiments will be needed to determine the molecular nature and biological properties of the various species, including the 60-kDa species found in this study. Hyperprolactinemia has been found in subsets of SLE patients; the disease is more active in those with elevated serum FIG. 3 . Nb2 mitogenicity of conditioned medium from Con-A-nonstimulated (B) and Con-A-stimulated (S) PBMNC from control and SLE subjects. PBMNC were incubated for 3 days in the presence or absence of the mitogen (1.56 g/mL), and culture medium was assayed for PRL-like activity in the Nb2 lymphoma cell bioassay. Culture media from controls and SLE-PBMNC were also incubated before their assessment in the Nb2 cell assay with specific anti-hPRL antiserum at a final dilution of 1:100,000 (Ab). Results represent the mean Ϯ SE of three replicate experiments.
PRL levels (43) , raising the possibility that circulating PRL might have an extrapituitary source. Inasmuch as the results from this study argued against this possibility, as the major PRL circulating species in SLE subjects had a molecular size of 23 kDa in contrast to the 60-kDa form found in both normal and SLE-PBMNC, further investigation is needed to define the source of circulating PRL in hyperprolactinemic SLE subjects.
Conventional T cell mitogens have been shown to influence the production of PRL-like activity by immune cells (46) . At the concentration used (1.56 g/mL), Con-A did not modify Nb2 responsiveness compared to that in cultures grown in the absence of mitogen, but, on the other hand, it significantly increased PRL-like secretion by both normal and SLE-PBMNC. This observation is in line with previous reports on the effects of T cell mitogens on rat Nb2 lymphoma cells (47) as well as on the effects of these agents on the secretion of bioactive PRL-like species from PBMNC (46) .
Although the exact mode of action of PRL in autoimmunity is not yet completely elucidated, experimental hyperprolactinemia has been associated with characteristic Th2 cells cytokine production (48) . These data suggest that PRLdriven cytokine production by Th2 cells could stimulate lymphocytes or microenvironmental cells, leading to a deterioration of the autoimmune process. Therefore, additional studies aimed at analyzing the mechanisms and pathways regulating PRL expression on lymphoid cells might provide us with new insights on the role of PRL in both normal and pathological immune conditions.
FIG. 4.
Western blot analysis of immunoreactive PRL-like molecules from normal and SLE Con-A-stimulated-PBMNC. Cell extracts were immunoprecipitated with specific hPRL antisera and subjected to SDS-PAGE on reducing conditions. PRL molecules were identified by Western blots. Lane 1, Human pituitary PRL (NIDDK hPRL RP-2); lane 2, serum from a SLE subject; lanes 3 and 4, cell lysates from two SLE subjects; lanes 5 and 6, cell lysates from normal individuals. Molecular size markers are shown on the left. Negative results were obtained when normal rabbit serum was used instead of antihPRL antiserum (not shown). 
